Eduovisual
Behavioral Health
Postpartum depression: screening and treatment
— Affects ~1 in 7 (~13%) of US birthing patients; higher in adolescents, low-income, and patients of color where access barriers compound risk.
— Leading cause of maternal morbidity; suicide and overdose together are a top cause of pregnancy-related death in the first postpartum year.
— New mother at 2-week, 6-week, or well-child visit endorsing tearfulness, anhedonia, poor sleep beyond infant care demands, guilt about mothering, or intrusive thoughts of harm to self or infant.
— Failure to thrive infant, missed well-child visits, or partner reporting "she's not herself."
— Prior depression/anxiety (strongest), prior PPD (~50% recurrence), family history of mood disorder.
— Unintended pregnancy, IPV, lack of social support, NICU admission, breastfeeding difficulties, pregnancy loss history.
— Thyroid dysfunction and severe anemia mimic or worsen symptoms — always check.
— Postpartum blues: transient, peaks day 4–5, resolves by day 14, no functional impairment.
— PPD: ≥2 weeks of MDE criteria, impairs function or bonding.
— Postpartum psychosis: psychiatric emergency, rapid onset within 2 weeks, hallucinations/delusions often centered on infant, bipolar spectrum until proven otherwise.
Board pearl: If a stem describes symptoms persisting beyond 2 weeks postpartum with functional impairment or guilt/worthlessness, it is PPD, not blues — and the next best step is a validated screen plus safety assessment, not reassurance.
— Sleep: inability to sleep even when the baby sleeps (key distinguishing feature from normal new-parent fatigue).
— Interest: anhedonia, including loss of pleasure in the infant; mothers may say "I feel like a bad mother" or "I don't feel connected."
— Guilt: ruminative guilt about parenting capability; worthlessness.
— Energy, Concentration, Appetite changes, Psychomotor changes.
— Suicidality, infanticidal ideation — always asked explicitly.
— Intrusive, ego-dystonic thoughts of accidentally harming the baby (dropping, contaminating) — distressing to mother and not the same as psychotic command hallucinations.
— Hypervigilance, checking on infant breathing repeatedly, panic attacks.
— Onset relative to delivery, prior mood episodes, prior PPD, bipolar features (any history of mania/hypomania must be screened — antidepressant monotherapy can precipitate mania).
— Thyroid symptoms, anemia symptoms, bleeding, infection.
— Substance use including alcohol and cannabis postpartum.
— Breastfeeding status (affects medication choice and counseling).
— Social: partner support, IPV screen, housing, childcare, finances.
— Delusions about the infant being evil, switched, or needing to be "saved."
— Command auditory hallucinations.
— Waxing/waning sensorium.
Key distinction: Intrusive thoughts of harm in PPD are ego-dystonic — the mother is horrified by them and avoids the baby out of fear. In psychosis, thoughts are ego-syntonic and acted-upon risk is high. Both require urgent intervention, but disposition differs: outpatient intensification vs emergency psychiatric admission.
Step 3 management: At every postpartum encounter (including pediatric well-child visits, where ACOG/AAP endorse screening the mother), explicitly ask about thoughts of harming self or the baby and document the answer.
— Disheveled grooming compared to prior visits, poor eye contact, tearfulness, flat affect.
— Slowed speech and psychomotor retardation, or agitation/pacing.
— Infant present: assess interaction — does mother soothe, make eye contact, respond to cues? Lack of bonding behaviors is a concerning finding.
— Thyroid exam: goiter, tremor, tachycardia (hyperthyroidism) or bradycardia, dry skin, delayed reflex relaxation (hypothyroidism). Postpartum thyroiditis classically presents 2–6 months postpartum with a hyperthyroid phase then hypothyroid phase.
— Pallor, tachycardia: suggest postpartum anemia or occult hemorrhage.
— Fever, uterine tenderness, foul lochia: endometritis.
— Mastitis, perineal/C-section wound infection — pain and sleep loss worsen mood.
— Orientation, thought process (linear vs disorganized), thought content (delusions, paranoia, intrusive thoughts), perceptions (hallucinations), insight, judgment.
— Cognition: acute confusion → think delirium, sepsis, or psychosis, not PPD.
— Ideation (passive vs active), plan, intent, access to means (firearms in home, stockpiled medications).
— Protective factors: reasons for living, infant attachment, supports.
— Use Columbia Suicide Severity Rating Scale (C-SSRS) or equivalent structured tool.
— Ability to care for infant, presence of another adult, history of any harm to infant.
Board pearl: Postpartum thyroiditis is a high-yield mimic — order TSH in any patient with new postpartum mood symptoms. Treating hypothyroidism alone can resolve depressive symptoms when thyroid is the driver, and missing it is a classic Step 3 trap distinguishing thoughtful workup from reflexive SSRI prescribing.
— USPSTF Grade B: screen all pregnant and postpartum patients for depression; ACOG recommends screening at least once during the perinatal period and again at the comprehensive postpartum visit.
— AAP recommends screening mothers at the 1-, 2-, 4-, and 6-month well-child visits.
— Edinburgh Postnatal Depression Scale (EPDS): 10 items, score ≥10 suggests possible depression, ≥13 likely depression; item 10 specifically asks about self-harm — review it individually regardless of total score.
— PHQ-9: also validated postpartum; ≥10 = moderate, ≥15 = moderately severe, ≥20 = severe; item 9 captures suicidality.
— Positive screen is not a diagnosis — confirm with diagnostic interview using DSM-5 criteria.
— TSH (postpartum thyroiditis).
— CBC (anemia from peripartum blood loss; iron deficiency worsens fatigue and mood).
— Ferritin if anemic or fatigue-predominant.
— Comprehensive metabolic panel if any concern for hepatic/renal disease (affects drug choice).
— Vitamin D, B12 if clinically suggested.
— Urine toxicology if substance use suspected — counsel about implications first; mandatory reporting laws vary by state.
— Neuroimaging, EEG, extensive autoimmune panels — only if focal neuro signs, atypical features, or first-episode psychosis.
Step 3 management: Positive EPDS or PHQ-9 → next steps are (1) suicide/infanticide risk assessment, (2) confirm diagnosis by interview, (3) check TSH and CBC, (4) initiate treatment plan with shared decision-making. Do not simply "repeat screen in 2 weeks" if score is positive and symptoms are present — that delay is a common wrong answer.
— ≥5 of 9 symptoms (SIGECAPS + depressed mood) for ≥2 weeks, including either depressed mood or anhedonia.
— Causes functional impairment.
— Not attributable to substance, medication, or another medical condition.
— Onset during pregnancy or within 4 weeks postpartum per DSM-5 (clinically extended to 12 months).
— MDQ (Mood Disorder Questionnaire) or direct history of prior manic/hypomanic episodes, antidepressant-induced mania, postpartum psychosis (highly associated with bipolar I).
— Positive bipolar screen → antidepressant monotherapy is contraindicated; refer to psychiatry, consider mood stabilizer or atypical antipsychotic.
— Comorbid postpartum anxiety/OCD — assess with GAD-7; intrusive thoughts may be OCD-spectrum.
— Comorbid PTSD — traumatic birth, NICU stay, prior trauma; PCL-5 screen.
— Substance use disorder — CAGE-AID, AUDIT-C; opioid use disorder requires MAT referral.
— Persistent insomnia despite infant sleeping → suggests true depressive insomnia rather than situational.
— Hypersomnia plus mood reactivity → consider atypical depression features.
— New focal deficits, seizure, severe headache → exclude postpartum cerebral venous sinus thrombosis, posterior reversible encephalopathy syndrome (PRES), pituitary apoplexy (Sheehan syndrome with hyponatremia).
Key distinction: Postpartum blues does not meet duration or impairment criteria and resolves by day 14. If symptoms persist beyond 2 weeks or impair functioning at any point, move to PPD diagnosis. Conversely, postpartum psychosis with mood symptoms within days of delivery raises strong suspicion for bipolar I, and SSRI monotherapy can precipitate mania — a frequently tested error.
— Mild PPD (PHQ-9 5–9, EPDS 10–12, no suicidality, preserved function): psychotherapy first-line, particularly CBT or interpersonal therapy (IPT); consider peer support, exercise, sleep optimization; reassess in 2 weeks.
— Moderate PPD (PHQ-9 10–14, EPDS 13–19): psychotherapy plus pharmacotherapy (SSRI) — combination is superior to either alone for moderate-severe disease.
— Severe PPD (PHQ-9 ≥15, EPDS ≥20, suicidality, severe functional impairment, inability to care for infant): pharmacotherapy required; consider rapid-acting agents (brexanolone, zuranolone), psychiatric referral, possible hospitalization.
— Patient preferences regarding medication, especially with breastfeeding.
— Prior treatment response — restart what worked previously; avoid agents that previously failed or caused intolerable side effects.
— Time-to-benefit considerations: SSRIs 4–6 weeks for full effect; zuranolone 3 days; brexanolone 60 hours.
— Sleep protection: have partner/support handle 1 nighttime feeding to allow a 4–5 hour consolidated sleep block (sleep deprivation is both a symptom and an exacerbator).
— Exercise, social support, infant care assistance.
— Address breastfeeding difficulties — lactation consultation.
— IPV screening and resources.
— Do not send home alone; arrange continuous supervision; involve psychiatry emergently; consider voluntary or involuntary hospitalization.
Step 3 management: The exam favors combined therapy (SSRI + psychotherapy) for moderate-severe PPD, psychotherapy alone for mild PPD, and psychiatric emergency department referral for active suicidal/infanticidal ideation or psychosis. Match severity to intensity — over- or under-treating either way is a graded wrong answer.
— Sertraline is the preferred agent — extensive safety data, low transfer into breast milk, undetectable infant serum levels in most studies. Start 25–50 mg daily, titrate to 50–200 mg.
— Escitalopram also low milk transfer, well tolerated; 5–10 mg start, up to 20 mg.
— Avoid fluoxetine as first choice in breastfeeding due to long half-life and active metabolite accumulating in infant; reasonable if previously effective.
— Avoid paroxetine in pregnancy (cardiac malformation signal); in lactation, paroxetine has low milk transfer but is not first-line.
— Expect 2–4 weeks for partial response, 4–8 weeks for full response; continue for ≥6–12 months after remission to prevent relapse.
— Side effects: nausea, sexual dysfunction, sleep changes, transient anxiety; usually resolve in 1–2 weeks.
— Black box warning for suicidality in patients <25 — many postpartum patients fall in this range; reassess at 1–2 weeks.
— Discontinuation syndrome if stopped abruptly — taper.
— SNRIs (venlafaxine, duloxetine) if SSRI failure or comorbid pain.
— Bupropion — avoid if seizure risk or breastfeeding with prior infant seizure; can be useful when sexual side effects limit SSRIs.
— Mirtazapine for prominent insomnia and weight loss.
— Brexanolone (Zulresso): IV infusion over 60 hours, inpatient under REMS due to sedation/syncope risk.
— Zuranolone (Zurzuvae): oral, 50 mg nightly × 14 days, FDA-approved 2023 for PPD; rapid onset within 3 days; avoid operating vehicles; contraception required.
Board pearl: Sertraline is the answer for a breastfeeding patient with PPD requiring an SSRI on Step 3 — high yield, repeatedly tested.
— Preferred: sertraline, paroxetine (low milk levels), escitalopram.
— Acceptable with monitoring: citalopram, fluoxetine (monitor infant for irritability, poor feeding, especially in preterm/young infants).
— Caution: doxepin (sedation, respiratory depression in infants — avoid); lithium (high milk transfer, infant levels ~25–50% of maternal — monitor infant TSH, BUN, lithium level if used).
— LactMed database is the practical reference; reassure patients that for most SSRIs, benefits of treatment + continued breastfeeding outweigh risks.
— Confirm adherence, adequate dose, adequate duration.
— Switch to another SSRI or to SNRI (cross-taper).
— Augment with psychotherapy if not already in place.
— Consider neuroactive steroid (zuranolone) for rapid response, especially with severe symptoms.
— ECT — highly effective, rapid onset, safe in pregnancy and lactation, indicated for severe PPD with suicidality, psychotic features, catatonia, or treatment resistance.
— TMS — option, but logistically difficult postpartum.
— Psychiatric inpatient admission with mother-baby unit if available.
— Mood stabilizer first: lamotrigine (low milk transfer, well tolerated), quetiapine, lurasidone.
— Avoid valproate in patients of reproductive age (teratogenicity, future pregnancies).
— Lithium effective but requires close monitoring.
— Atypical antipsychotic + mood stabilizer; consider ECT; hospitalize.
Step 3 management: Inadequate response at 4–6 weeks of an adequately dosed SSRI → optimize dose first, then switch or augment. Do not abandon SSRI class after one trial without dose optimization — a frequent distractor on the exam.
— Higher rates of pregnancy complications (preeclampsia, GDM, preterm delivery) that increase PPD risk.
— Often higher socioeconomic resources but also greater isolation if friends not in same life stage; screen for social support gaps.
— Drug pharmacokinetics largely unchanged; standard SSRI dosing applies.
— Most SSRIs metabolized hepatically (CYP2D6, 2C19, 3A4). In moderate-severe hepatic disease:
— Start at half the usual dose and titrate slowly.
— Sertraline has dose-related hepatotoxicity case reports — monitor LFTs if pre-existing disease.
— Avoid duloxetine in chronic liver disease/heavy alcohol use (boxed warning).
— Acute fatty liver of pregnancy or HELLP-related hepatic injury in recent postpartum — defer initiation until LFTs trending down.
— SSRIs largely safe; dose adjust venlafaxine, desvenlafaxine, paroxetine in CrCl <30.
— Lithium contraindicated in significant CKD.
— Watch hyponatremia (SIADH) with SSRIs/SNRIs, particularly in older patients or those on diuretics; check sodium at 2–4 weeks if risk factors.
— Citalopram has QT prolongation warning — limit to 20 mg in patients >60, hepatic impairment, or on QT-prolonging agents; escitalopram has less QT effect and is preferred.
— Avoid TCAs in cardiac conduction disease.
— Avoid bupropion (lowers seizure threshold) and high-dose SSRIs without titration.
— Treat iron deficiency — repletion alone can substantially improve fatigue and mood; check ferritin in any postpartum patient with fatigue-predominant symptoms.
Board pearl: A postpartum patient on a thiazide and an SSRI presenting with confusion and nausea at 3 weeks → check serum sodium — SSRI-induced SIADH is a tested complication, especially with concurrent diuretic use.
— 2–3× higher PPD rates; lower screening rates and lower treatment uptake.
— Confidentiality nuances — many states allow minors to consent to mental health treatment for themselves; parental involvement is helpful when safe.
— School re-entry and childcare logistics are mental health interventions.
— PPD risk is markedly elevated; differentiate from prolonged grief disorder (>12 months, impairing yearning).
— Treat MDE if criteria met; do not pathologize normal acute grief at <6 months.
— Specialized bereavement counseling.
— Both parents at high risk for PPD, PTSD, anxiety. Screen mothers (and fathers/partners — paternal PPD affects ~10%).
— Encourage skin-to-skin, kangaroo care, milk donation when feasible to support bonding.
— Adoptive mothers can develop depressive symptoms with bonding stress — same psychotherapy principles apply; pharmacology not affected by lactation considerations unless inducing lactation.
— Surrogates have hormonal postpartum changes plus unique grief; screen.
— Stigma around mental illness varies; framing as "stress" or "fatigue" may improve engagement.
— Use validated translations of EPDS (available in 60+ languages).
— Postpartum traditions (e.g., 40-day confinement) can be protective or isolating; assess individually.
— Higher trauma burden; PTSD comorbidity common; ensure trauma-informed care and continuity through transfers.
— MAT (buprenorphine, methadone) is compatible with breastfeeding; do not discontinue for PPD treatment.
— Coordinate with addiction medicine.
Step 3 management: At every NICU and pediatric visit, screen the mother — AAP and ACOG endorse maternal depression screening at well-child visits, and this is a tested transitions-of-care expectation for the family physician or pediatrician.
— Suicide: leading cause of maternal mortality in the first postpartum year in many US datasets; risk peaks 6–12 months postpartum, when surveillance has typically waned.
— Substance use disorder — alcohol, opioids, benzodiazepines as self-medication.
— Chronic depression — untreated PPD predicts recurrent MDE outside of pregnancy.
— Worsened management of medical comorbidities (DM, HTN, thyroid).
— Reduced uptake of contraception → unintended pregnancy → cycle of risk.
— Impaired mother-infant bonding and attachment.
— Lower rates of breastfeeding initiation and continuation.
— Failure to thrive, missed well-child visits, missed vaccinations.
— Long-term: cognitive, language, and socioemotional developmental delays; increased childhood behavioral problems and later depression risk.
— Rare but catastrophic: infanticide, almost always in the setting of postpartum psychosis rather than uncomplicated PPD.
— Partner depression (concordance ~25–50%).
— Marital strain, IPV escalation.
— Sibling psychosocial impact.
— Increased ED visits, missed postpartum visit (already only ~60% attendance nationally).
— Higher healthcare costs; PPD is a high-value target for population health programs.
— SSRI side effects: GI upset, sexual dysfunction, sleep disturbance, hyponatremia.
— Discontinuation syndrome if abrupt cessation.
— Serotonin syndrome with concomitant tramadol, triptans, linezolid, MAOIs.
— Neonatal adaptation syndrome if exposure was late pregnancy (jitteriness, feeding difficulty, transient — not PPHN signal alone).
Board pearl: A postpartum patient who endorses thoughts of harming her baby on EPDS item 10 but is horrified by these thoughts is most likely experiencing intrusive OCD-spectrum thoughts within PPD/postpartum OCD, not psychosis — risk to infant is low, but treatment urgency is high.
— Active suicidal ideation with plan or intent, or recent attempt.
— Postpartum psychosis — any psychotic symptoms (delusions, hallucinations, disorganization, fluctuating sensorium) in the postpartum period is a psychiatric emergency; risk of suicide ~5% and infanticide ~4% without treatment.
— Active infanticidal ideation with plan, command hallucinations to harm infant, or delusional beliefs about the infant.
— Catatonia, severe agitation, or inability to care for self or infant.
— Severe medication side effects (serotonin syndrome, NMS).
— Inpatient psychiatric admission for the above emergencies; ideal: mother-baby psychiatric unit if available (more common in UK/Europe, expanding in US).
— Partial hospitalization / IOP for moderate-severe PPD failing outpatient care without imminent safety risk.
— Identify red flag → ensure safety (1:1 sitter, remove means) → consult psychiatry → arrange transport (do not allow patient to drive herself) → admit voluntarily; if refuses and meets criteria for danger to self/others, involuntary hold per state statute.
— Arrange care for the infant — ensure a safe adult caregiver; involve social work; CPS notification is usually not required for PPD alone but is required if there is imminent risk to the child or actual neglect/harm.
— Psychiatry (reproductive psychiatry if available), social work, lactation, OB/GYN, primary care for medical comorbidities, pediatrics for infant safety planning.
CCS pearl: For a patient with severe PPD and suicidal ideation refusing admission, the sequence is: establish 1:1 supervision → psychiatric consult → involuntary hold paperwork → arrange infant care → admit. Allowing the patient to leave AMA when she meets hold criteria is a graded patient-safety error.
— Up to 80% of mothers; mood lability, tearfulness, brief.
— Onset days 2–5, resolves by day 14, no functional impairment, no anhedonia or suicidality.
— Management: reassurance, sleep, support.
— Generalized anxiety, panic, or specific phobia phenotypes.
— May coexist with PPD; treat with SSRI + CBT.
— Intrusive, ego-dystonic thoughts (often about infant harm/contamination), compulsions (checking, cleaning).
— Treat with SSRI (often higher doses) + exposure-response prevention therapy.
— Key distinction from psychosis: thoughts are unwanted and distressing; insight is preserved.
— Traumatic delivery (emergency C-section, hemorrhage, NICU), prior trauma.
— Hyperarousal, intrusion, avoidance; treat with trauma-focused CBT, EMDR, SSRI/SNRI.
— 1–2/1000 deliveries; onset usually within 2 weeks, often within days.
— Strong link to bipolar I disorder — 50–80% have or will develop bipolar.
— Delusions, hallucinations, disorganization, rapid fluctuation; inpatient admission required.
— Treatment: antipsychotic + mood stabilizer ± ECT.
— Personal/family history of bipolar; antidepressant-induced switching.
— Treat with mood stabilizer (lamotrigine, quetiapine, lurasidone) — not antidepressant monotherapy.
— Identifiable stressor, subthreshold symptoms, time-limited.
Key distinction: Postpartum OCD intrusive thoughts (ego-dystonic, mother avoids baby) vs postpartum psychosis command hallucinations/delusions (ego-syntonic, may act on them). Both need urgent care, but OCD is outpatient-treatable while psychosis demands hospitalization — a high-yield Step 3 vignette discriminator.
— 5–10% of postpartum patients; classic triphasic course (hyper → hypo → euthyroid) over 12 months.
— Hypothyroid phase (3–6 months postpartum) mimics depression: fatigue, weight gain, cognitive slowing, low mood.
— TSH is the screening test; treat hypothyroid phase with levothyroxine if symptomatic or TSH >10.
— Common after peripartum hemorrhage; fatigue, dyspnea, poor concentration.
— CBC, ferritin; oral or IV iron repletion.
— Pituitary infarction after postpartum hemorrhage; failure to lactate, amenorrhea, fatigue, hyponatremia, secondary adrenal insufficiency.
— Check prolactin, cortisol, TSH/free T4, FSH/LH; pituitary MRI.
— B12, folate, vitamin D — all can cause fatigue and depressive symptoms; common in restrictive diets, post-bariatric surgery patients.
— Alcohol, cannabis, opioids, stimulants — both withdrawal and intoxication mimic mood disorders.
— Obstructive sleep apnea worsens postpartum, especially with weight retention and breast tissue changes.
— Infection (endometritis, pyelonephritis, mastitis), DVT/PE (dyspnea, anxiety), peripartum cardiomyopathy (fatigue, edema), autoimmune flare (lupus, MS).
— Postpartum preeclampsia can present up to 6 weeks postpartum with headache, vision changes, hypertension — sometimes mistaken for anxiety.
— Hormonal contraceptives (progestin-only DMPA most implicated), beta-blockers, corticosteroids, isotretinoin.
Board pearl: Always check TSH and CBC before locking in PPD as the diagnosis. A vignette with postpartum hemorrhage and persistent fatigue + amenorrhea + failure to lactate is Sheehan syndrome, not PPD — and the next step is AM cortisol, TSH, prolactin, not an SSRI.
— First episode of PPD: continue antidepressant for ≥6–12 months after achieving remission, then consider taper.
— Recurrent depression (≥2 episodes) or severe/suicidal first episode: indefinite maintenance therapy is reasonable.
— Taper slowly over 4+ weeks to avoid discontinuation syndrome.
— Maintenance psychotherapy (monthly CBT/IPT "booster" sessions).
— Sleep hygiene, exercise, social engagement.
— Identify early warning signs and create a written relapse-prevention plan.
— Prior PPD confers ~50% recurrence risk in next pregnancy.
— Preconception counseling: discuss continuation vs discontinuation of antidepressants; most patients should continue effective antidepressants in pregnancy — relapse risk is high.
— Sertraline preferred in pregnancy as in lactation; avoid paroxetine (cardiac malformation signal) and valproate (NTDs).
— Plan prophylactic restart of antidepressant immediately postpartum for high-risk patients (history of PPD).
— Critical to prevent unintended pregnancy that increases risk.
— Avoid DMPA if mood-sensitive; LARCs (IUD, implant) ideal.
— Continue depression screening at every primary care visit for at least 12 months.
— Cardiometabolic screening if on antipsychotics (weight, lipids, glucose).
— Address modifiable factors: thyroid, anemia, vitamin D.
— Warm handoff from OB to PCP at 12-week postpartum visit ("fourth trimester" framework).
— Communicate medication plan to pediatrician.
Step 3 management: For a patient with prior severe PPD planning another pregnancy, the right answer is usually continue SSRI through pregnancy and postpartum rather than discontinue — risk of untreated maternal depression to mother and fetus outweighs medication risk for most SSRIs.
— 1–2 weeks after initiating or changing antidepressant: assess tolerability, side effects, suicidality (especially given black box warning).
— 4 weeks: assess early response (≥20% symptom reduction); if absent, optimize dose.
— 6–8 weeks: assess for remission (PHQ-9 <5); if not achieved at adequate dose, switch or augment.
— Every 3 months during maintenance; every visit during taper.
— Baseline TSH, CBC, BMP.
— Sodium at 2–4 weeks in patients at risk for SSRI-induced hyponatremia (older age, diuretics, low baseline Na).
— LFTs if hepatic risk factors or on duloxetine.
— If on lithium: levels, TSH, creatinine every 3–6 months; infant levels if breastfeeding.
— If on atypical antipsychotic: weight, BP, fasting glucose, lipids at 3 months then annually.
— Repeat PHQ-9 or EPDS at every visit to track response objectively (measurement-based care).
— Explicit suicide reassessment at every encounter.
— CBT or IPT weekly for 12–16 sessions, then taper to biweekly/monthly.
— Group therapy and peer support (e.g., Postpartum Support International) — adjuncts with good evidence.
— PPD is a medical illness, not a character flaw or parenting failure.
— Treatment is effective; expect gradual improvement.
— Continue medication even when feeling better.
— Call urgently if suicidal/infanticidal thoughts emerge or worsen.
— Engage support network; sleep and exercise matter.
— Inform pediatrician of medication if breastfeeding; monitor infant growth, feeding, behavior.
CCS pearl: Use measurement-based care — order or document a PHQ-9 at each follow-up rather than relying on global impression. Step 3 grading rewards objective monitoring and explicit suicidality reassessment.
— Discuss known and unknown risks of medication transfer; document shared decision-making.
— Frame: "untreated depression also carries risks to mother and infant" — avoids one-sided risk presentation.
— Patient has autonomy to choose continued breastfeeding with treatment, formula feeding with treatment, or to decline treatment after capacity-confirmed discussion.
— Severe depression with hopelessness or psychosis may impair capacity to refuse treatment.
— Document the 4 elements: understanding, appreciation, reasoning, expression of a choice.
— When capacity is lacking and risk is imminent, proceed with involuntary treatment per state statute.
— PPD alone is not reportable. CPS involvement is required only when there is actual or imminent harm or neglect of the child.
— Reporting solely for maternal mental illness can deter care-seeking — a documented public health harm.
— When the mother is hospitalized for psychiatric care, ensure infant has a safe caregiver; involve social work rather than reflexively calling CPS.
— In most states, mental health treatment of minors can be consented to by the minor; clarify state-specific rules.
— Do not disclose to partners without consent unless safety exception applies.
— Screen privately, without partner present.
— If disclosed, provide resources; reporting is not mandatory in most states for competent adults but is required if a child is being abused.
— The postpartum-to-primary-care handoff is a notorious failure point; standardize a warm handoff with documented medication list, screening scores, and follow-up plan.
— Communicate with pediatrician about maternal medications (HIPAA permits as treatment-related).
— Lethal means counseling — particularly firearms (highest case-fatality method); request safe storage or temporary off-site storage.
— Provide Crisis line (988) at every visit.
Board pearl: Calling CPS for a mother with PPD who is engaged in treatment and has a safe caregiver for her infant is the wrong answer — it harms the therapeutic alliance and is not legally required. Mandatory reporting is triggered by harm to the child, not by maternal diagnosis.
Step 3 management: When in doubt on a vignette, sertraline + CBT + close follow-up + safety plan is the highest-yield management answer for outpatient moderate PPD.
Board pearl: The most common Step 3 trap is reaching for an SSRI before ruling out bipolar disorder, thyroid disease, and severe suicidality/psychosis. Always pause for the safety + medical mimic check first.
Postpartum depression is a common, treatable medical illness affecting ~1 in 7 birthing patients in the year after delivery, screened universally with EPDS or PHQ-9, treated with psychotherapy for mild disease and SSRI (sertraline preferred, including in breastfeeding) plus psychotherapy for moderate-severe disease, while postpartum psychosis and active suicidality are psychiatric emergencies requiring hospitalization.
Board pearl: When the vignette asks "next best step," the answer is almost always the one that simultaneously addresses safety, confirms diagnosis, and starts evidence-based treatment: screen → suicide/bipolar/thyroid check → sertraline + CBT + close follow-up → escalate to hospitalization only when safety demands it.